Abstract: Disclosed herein are methods for treating an individual having a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The method may comprise administering a JAK inhibitor, for example ruxolitinib (JAKAFIĀ®), to an individual in need thereof, such individual generally being an individual having, or suspecting of having, SARS-CoV-2 infection. The individual in need thereof may be an individual having, or suspected of having or at risk for developing SARS-CoV-2 infection-related cytokine storm. The individual in need thereof may further be an individual having, or suspected of having SARS-CoV-2 infection-related pneumonia.
Abstract: Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.
Type:
Grant
Filed:
November 20, 2018
Date of Patent:
April 12, 2022
Assignees:
JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC., HEALTHQUEST PHARMA INC.
Inventors:
Yifan Zhai, Xiaoyong Zhang, Jinlin Hou, Dajun Yang
Abstract: A composition for inhibiting sodium leakage channel (NALCN), including as an active ingredient N-benzhydryl quinuclidine (NBQN) or a N-benzhydryl quinuclidine derivative represented by the following Formula 1, wherein in the following Formula 1, R is an unsubstituted or substituted benzyl group
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
April 12, 2022
Assignee:
Research & Business Foundation Sungkyunkwan University
Inventors:
Myoung Kyu Park, Hyun Jin Kim, Suyun Hahn, So Woon Kim
Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.
Type:
Grant
Filed:
April 13, 2020
Date of Patent:
March 29, 2022
Assignee:
Oncternal Therapeutics, Inc.
Inventors:
Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
Abstract: The invention provides pharmaceutical compositions and methods of use thereof for treating Prader-Willi syndrome. More specifically, the invention provides pharmaceutical compositions that when administered inhibit the G9a driven methylation of histone H3 lysine 9.
Type:
Grant
Filed:
May 17, 2017
Date of Patent:
March 22, 2022
Assignees:
Duke University, The University of North Carolina at Chapel Hill
Inventors:
Yong-hui Jiang, Yuna Kim, Hyeong-min Lee, Jian Jin, Bryan L. Roth
Abstract: The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
Abstract: The present invention is directed to pesticidal mixtures comprising sabadilla alkaloids and azadirachtin and methods of controlling pests including insects and mites by application of pesticidal mixtures comprising sabadilla alkaloids and azadirachtin.
Abstract: The present disclosure relates to an orally administered pharmaceutical formulation containing an inclusion complex formed as varenicline or a pharmaceutically acceptable salt thereof is included in cyclodextrin. The pharmaceutical formulation can improve convenience of medication by effectively masking the bitter taste of the drug and the irritation during swallowing, can provide the oxidation stability of varenicline and can improve the solubility of the drug.
Type:
Grant
Filed:
March 2, 2018
Date of Patent:
March 8, 2022
Assignee:
CTC BIO, INC.
Inventors:
Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Seul Ki Meang, Su-Jun Park, Seong-Shin Kwak
Abstract: There are disclosed methods of treatment of viral infection. The method makes use of administration of an anti-Hsc70 inhibitor. There are also disclosed uses of anti-Hsc70 inhibitor.
Abstract: The present invention relates to a method of increasing cell proliferation in a population of pancreatic beta cells and a method of treating a subject for a condition associated with an insufficient level of insulin secretion. Also disclosed is a composition. The composition includes a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1 A) inhibitor and a transforming growth factor beta (TGFP) superfamily signaling pathway inhibitor.
Abstract: Provided are methods of using oleanolic acid and derivatives for treating coronavirus infection. The method includes using propargyl-moiety containing oleanolic acid derivatives for inhibiting coronavirus growth by impairing the viral replication of SARS-CoV-2 through inhibition of the viral function of SARS-CoV-2 main protease.
Type:
Grant
Filed:
July 20, 2021
Date of Patent:
March 8, 2022
Assignee:
KING ABDULAZIZ UNIVERSITY
Inventors:
Raya Soltane, Hani Abdullah Alhadrami, Ahlam Alasiri, Hichem Ben Jannet, Karim Chouaib, Amani Chrouda, Ahmed Mostafa, Rami Adel Pashameah
Abstract: A pharmaceutical composition for preventing or treating diabetic nephropathy is provided. According to the present invention, a pharmaceutical composition for preventing or treating diabetic nephropathy comprises an adenosine derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient.
Type:
Grant
Filed:
July 6, 2018
Date of Patent:
March 8, 2022
Assignee:
FUTURE MEDICINE CO., LTD.
Inventors:
Hea Ok Kim, Chong-Woo Park, Mi Ra Yu, Bo Mi Park
Abstract: A dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B, specifically, is a compound having Formula (I) or (Ia), or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification; and also includes the use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.
Abstract: The present invention pertains to a composition for preparing a medicament for preventing and/or treating a virus infection, especially a hepatitis B virus infection and/or a herpes simplex virus, and uses thereof.
Type:
Grant
Filed:
February 25, 2020
Date of Patent:
February 22, 2022
Assignee:
ARJIL BIOTECH HOLDING COMPANY LIMITED
Inventors:
Yeh B Wu, Jir-Mehng Lo, Hui Ju Liang, Pei-Hsin Lin, Cheng Huang
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type:
Grant
Filed:
March 17, 2020
Date of Patent:
February 22, 2022
Assignee:
Enanta Pharmaceuticals, Inc.
Inventors:
Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
Abstract: The present invention relates to a piperazine heteroaryl derivative, a preparation method therefor and the use of same in medicine. In particular, the present invention relates to the piperazine heteroaryl derivative as shown in the general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and the use of same as a capsid protein inhibitor, in particular in the prevention and/or treatment of diseases such as hepatitis B, influenza, herpes, AIDS, etc. The definitions of each group in the general formula (I) are the same as those defined in the description.
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.